Trial reportInflammation2012
Regulation of oxidative stress in patients with Kawasaki disease.
Trial report in Inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Corticosteroids for the treatment of Kawasaki disease in children.The Cochrane database of systematic reviews · 2022Pooled it
- Corticosteroids for the treatment of Kawasaki disease in children.The Cochrane database of systematic reviews · 2017Pooled it
- An integrated and interpretable machine learning framework for Kawasaki disease diagnosis and risk prediction.Translational pediatrics · 2025Article
- Markers of Endothelial Dysfunction in Kawasaki Disease: An Update.Clinical reviews in allergy & immunology · 2024Review
- Sputum microbe community alterations induced by long-term inhaled corticosteroid use are associated with airway function in chronic obstructive pulmonary disease patients based on metagenomic next-generation sequencing (mNGS).Frontiers in pharmacology · 2024Article
- A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19.Clinical medicine insights. Pediatrics · 2022Review
- New biomarkers of Kawasaki disease identified by urine proteomic analysis.FEBS open bio · 2019Article
- Pathogenetic determinants in Kawasaki disease: the haematological point of view.Journal of cellular and molecular medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although there is ample evidence that Kawasaki disease (KD) is associated with vascular inflammation, few studies have addressed the influence of oxidative stress. The goal of this study was to determine whether oxidative stress contributes to inflammation during KD, and also whether corticosteroid therapy can reduce oxidative stress. Serum reduced glutathione (sGSH) and serum thioredoxin (sTRX) were measured during KD to evaluate the phase-dependent change in the redox state in KD. Additionally, the efficacy of the therapies to reduce oxidative stress was assessed. The sGSH level significantly decreased post-intravenous immunoglobulin (IVIG). The sGSH level significantly increased during the convalescent phase. The sTRX level was significantly lower during the convalescent phase than that during the pre- and the post-IVIG. There was no difference in the sGSH and sTRX changes between the IVIG therapy and the IVIG + prednisolone (PSL) therapy, except for the convalescent phase in sTRX. Systemic inflammation in KD induces changes in the redox state, whereas the IVIG + PSL therapy did not show any remarkable change on oxidative stress in comparison to the IVIG therapy. Therapeutic intervention against oxidative stress might therefore be beneficial as adjunctive therapies for KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.